(Q28193780)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12236927%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

review article

1 reference

title

Prevention and treatment of ischemic heart disease in patients with diabetes mellitus (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12236927%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

1 reference

coronary artery disease

1 reference

Héctor Bueno

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12236927%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

publication date

1 September 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12236927%20AND%20SRC:MED&resulttype=core&format=json

Revista Española de Cardiología

13 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12236927%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

volume

55

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12236927%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12236927%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

page(s)

975-986

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12236927%20AND%20SRC:MED&resulttype=core&format=json

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

13 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Diabetes mellitus: a major risk factor for cardiovascular disease. A joint editorial statement by the American Diabetes Association; The National Heart, Lung, and Blood Institute; The Juvenile Diabetes Foundation International; The National Institut

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

American Diabetes Association position statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

American Heart Association 2001 scientific sessions: late-breaking science-drug-eluting stents

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Final report on the aspirin component of the ongoing Physicians' Health Study

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Antithrombotic agents in coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Abciximab reduces mortality in diabetics following percutaneous coronary intervention.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Will diabetes save the platelet blockers?

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Withholding thrombolysis in patients with diabetes mellitus and acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronar

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb angioplasty substudy

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Timolol Treatment After Myocardial Infarction in Diabetic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Diabetic patients and beta-blockers after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients. Results from the National Cooperative Cardiovascular Project

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Secondary prevention of cardiovascular disease and diabetes: still suboptimal in patients with myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

The Effect of the Angiotensin-Converting–Enzyme Inhibitor Zofenopril on Mortality and Morbidity after Anterior Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Do interventions to reduce coronary heart disease reduce the incidence of type 2 diabetes? A possible role for inflammatory factors

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

Clinical outcomes in statin treatment trials: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0300-8932%2802%2976736-5

7 January 2021

10.1016/S0300-8932(02)76736-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12236927%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

1 reference